| Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ... New England journal of medicine 369 (2), 134-144, 2013 | 4249 | 2013 |
| Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... New England Journal of Medicine 371 (5), 424-433, 2014 | 3599 | 2014 |
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial C Robert, A Ribas, JD Wolchok, FS Hodi, O Hamid, R Kefford, JS Weber, ... The Lancet 384 (9948), 1109-1117, 2014 | 2161 | 2014 |
| Enzalutamide with standard first-line therapy in metastatic prostate cancer ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... New England Journal of Medicine 381 (2), 121-131, 2019 | 1451 | 2019 |
| Association of pembrolizumab with tumor response and survival among patients with advanced melanoma A Ribas, O Hamid, A Daud, FS Hodi, JD Wolchok, R Kefford, AM Joshua, ... Jama 315 (15), 1600-1609, 2016 | 1184 | 2016 |
| Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ... Annals of Oncology 30 (4), 582-588, 2019 | 914 | 2019 |
| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 830 | 2021 |
| Evaluation of immune-related response criteria and RECIST v1. 1 in patients with advanced melanoma treated with pembrolizumab FS Hodi, WJ Hwu, R Kefford, JS Weber, A Daud, O Hamid, A Patnaik, ... Journal of Clinical Oncology 34 (13), 1510-1517, 2016 | 782 | 2016 |
| Overall survival benefit with tebentafusp in metastatic uveal melanoma P Nathan, JC Hassel, P Rutkowski, JF Baurain, MO Butler, M Schlaak, ... New England Journal of Medicine 385 (13), 1196-1206, 2021 | 706 | 2021 |
| Programmed death-ligand 1 expression and response to the anti–programmed death 1 antibody Pembrolizumab in melanoma AI Daud, JD Wolchok, C Robert, WJ Hwu, JS Weber, A Ribas, FS Hodi, ... Journal of Clinical Oncology 34 (34), 4102-4109, 2016 | 679 | 2016 |
| Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma C Robert, A Ribas, O Hamid, A Daud, JD Wolchok, AM Joshua, WJ Hwu, ... Journal of clinical oncology 36 (17), 1668-1674, 2018 | 489 | 2018 |
| Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial RD Carvajal, JA Sosman, JF Quevedo, MM Milhem, AM Joshua, ... Jama 311 (23), 2397-2405, 2014 | 475 | 2014 |
| Absence of TMPRSS2: ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome M Yoshimoto, AM Joshua, IW Cunha, RA Coudry, FP Fonseca, ... Modern pathology 21 (12), 1451-1460, 2008 | 344 | 2008 |
| Pembrolizumab L Khoja, MO Butler, SP Kang, S Ebbinghaus, AM Joshua Journal for immunotherapy of cancer 3, 1-13, 2015 | 316 | 2015 |
| Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab RW Joseph, J Elassaiss-Schaap, R Kefford, WJ Hwu, JD Wolchok, ... Clinical Cancer Research 24 (20), 4960-4967, 2018 | 287 | 2018 |
| Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT) RD Carvajal, S Piperno-Neumann, E Kapiteijn, PB Chapman, S Frank, ... Journal of Clinical Oncology 36 (12), 1232-1239, 2018 | 279 | 2018 |
| Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study L Khoja, EG Atenafu, S Suciu, S Leyvraz, T Sato, E Marshall, U Keilholz, ... Annals of Oncology 30 (8), 1370-1380, 2019 | 264 | 2019 |
| Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial TL Stockley, AM Oza, HK Berman, NB Leighl, JJ Knox, FA Shepherd, ... Genome medicine 8, 1-12, 2016 | 263 | 2016 |
| Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. A Ribas, C Robert, FS Hodi, JD Wolchok, AM Joshua, WJ Hwu, JS Weber, ... Journal of Clinical Oncology 33 (15_suppl), 3001-3001, 2015 | 247 | 2015 |
| Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking M Poudineh, PM Aldridge, S Ahmed, BJ Green, L Kermanshah, V Nguyen, ... Nature nanotechnology 12 (3), 274-281, 2017 | 241 | 2017 |
Antoni RibasUCLAایمیل تأیید شده در mednet.ucla.edu
